147 related articles for article (PubMed ID: 16128938)
1. Effect on intragastric pH of a PPI with a prolonged plasma half-life: comparison between tenatoprazole and esomeprazole on the duration of acid suppression in healthy male volunteers.
Hunt RH; Armstrong D; James C; Chowdhury SK; Yuan Y; Fiorentini P; Taccoen A; Cohen P
Am J Gastroenterol; 2005 Sep; 100(9):1949-56. PubMed ID: 16128938
[TBL] [Abstract][Full Text] [Related]
2. Tenatoprazole, a novel proton pump inhibitor with a prolonged plasma half-life: effects on intragastric pH and comparison with esomeprazole in healthy volunteers.
Galmiche JP; Bruley Des Varannes S; Ducrotté P; Sacher-Huvelin S; Vavasseur F; Taccoen A; Fiorentini P; Homerin M
Aliment Pharmacol Ther; 2004 Mar; 19(6):655-62. PubMed ID: 15023167
[TBL] [Abstract][Full Text] [Related]
3. A comparative study of the early effects of tenatoprazole 40 mg and esomeprazole 40 mg on intragastric pH in healthy volunteers.
Galmiche JP; Sacher-Huvelin S; Bruley des Varannes S; Vavasseur F; Taccoen A; Fiorentini P; Homerin M
Aliment Pharmacol Ther; 2005 Mar; 21(5):575-82. PubMed ID: 15740541
[TBL] [Abstract][Full Text] [Related]
4. The pharmacodynamics and pharmacokinetics of S-tenatoprazole-Na 30 mg, 60 mg and 90 mg vs. esomeprazole 40 mg in healthy male subjects.
Hunt RH; Armstrong D; Yaghoobi M; James C
Aliment Pharmacol Ther; 2010 Mar; 31(6):648-57. PubMed ID: 20015104
[TBL] [Abstract][Full Text] [Related]
5. Comparison of the effects of fasting morning, fasting evening and fed bedtime administration of tenatoprazole on intragastric pH in healthy volunteers: a randomized three-way crossover study.
Thomson AB; Cohen P; Ficheux H; Fiorentini P; Domagala F; Homerin M; Taccoen A
Aliment Pharmacol Ther; 2006 Apr; 23(8):1179-87. PubMed ID: 16611279
[TBL] [Abstract][Full Text] [Related]
6. Intragastric acidity after switching from 5-day treatment with intravenous pantoprazole 40 mg/d to 5-day treatment with oral esomeprazole 40 mg/d or pantoprazole 40 mg/d: an open-label crossover study in healthy adult volunteers.
Miner PB; Tutuian R; Castell DO; Liu S; Sostek MB
Clin Ther; 2006 May; 28(5):725-33. PubMed ID: 16861094
[TBL] [Abstract][Full Text] [Related]
7. The effect of the area under the plasma concentration vs time curve and the maximum plasma concentration of esomeprazole on intragastric pH.
Junghard O; Hassan-Alin M; Hasselgren G
Eur J Clin Pharmacol; 2002 Oct; 58(7):453-8. PubMed ID: 12389067
[TBL] [Abstract][Full Text] [Related]
8. Intragastric acidity during treatment with esomeprazole 40 mg twice daily or pantoprazole 40 mg twice daily--a randomized, two-way crossover study.
Miehlke S; Madisch A; Kirsch C; Lindner F; Kuhlisch E; Laass M; Knoth H; Morgner A; Labenz J
Aliment Pharmacol Ther; 2005 Apr; 21(8):963-7. PubMed ID: 15813831
[TBL] [Abstract][Full Text] [Related]
9. Effect of esomeprazole and rabeprazole on intragastric pH in healthy Chinese: an open, randomized crossover trial.
Li ZS; Zhan XB; Xu GM; Cheng NN; Liao Z
J Gastroenterol Hepatol; 2007 Jun; 22(6):815-20. PubMed ID: 17565634
[TBL] [Abstract][Full Text] [Related]
10. Intragastric acid control in non-steroidal anti-inflammatory drug users: comparison of esomeprazole, lansoprazole and pantoprazole.
Goldstein JL; Miner PB; Schlesinger PK; Liu S; Silberg DG
Aliment Pharmacol Ther; 2006 Apr; 23(8):1189-96. PubMed ID: 16611280
[TBL] [Abstract][Full Text] [Related]
11. Review article: the opportunities and benefits of extended acid suppression.
Scarpignato C; Pelosini I
Aliment Pharmacol Ther; 2006 Jun; 23 Suppl 2():23-34. PubMed ID: 16700900
[TBL] [Abstract][Full Text] [Related]
12. A comparison of esomeprazole and lansoprazole for control of intragastric pH in patients with symptoms of gastro-oesophageal reflux disease.
Johnson DA; Stacy T; Ryan M; Wootton T; Willis J; Hornbuckle K; Brooks W; Doviak M
Aliment Pharmacol Ther; 2005 Jul; 22(2):129-34. PubMed ID: 16011671
[TBL] [Abstract][Full Text] [Related]
13. Effect of intravenous esomeprazole 40 mg and pantoprazole 40 mg on intragastric pH in healthy subjects. A prospective, open, randomised, two-way cross-over comparative study.
Piccoli F; Ory G; Hadengue A; Beglinger C; Degen L
Arzneimittelforschung; 2007; 57(10):654-8. PubMed ID: 18074759
[TBL] [Abstract][Full Text] [Related]
14. An open-label, parallel, multiple-dose study comparing the pharmacokinetics and gastric acid suppression of rabeprazole extended-release with esomeprazole 40 mg and rabeprazole delayed-release 20 mg in healthy volunteers.
Morelli G; Chen H; Rossiter G; Rege B; Lu Y
Aliment Pharmacol Ther; 2011 Apr; 33(7):845-54. PubMed ID: 21272047
[TBL] [Abstract][Full Text] [Related]
15. Intragastric acid suppression and pharmacokinetics of twice-daily esomeprazole: a randomized, three-way crossover study.
Katz PO; Castell DO; Chen Y; Andersson T; Sostek MB
Aliment Pharmacol Ther; 2004 Aug; 20(4):399-406. PubMed ID: 15298633
[TBL] [Abstract][Full Text] [Related]
16. Characterization of the inhibitory activity of tenatoprazole on the gastric H+,K+ -ATPase in vitro and in vivo.
Shin JM; Homerin M; Domagala F; Ficheux H; Sachs G
Biochem Pharmacol; 2006 Mar; 71(6):837-49. PubMed ID: 16405921
[TBL] [Abstract][Full Text] [Related]
17. Esomeprazole 40 mg i.v. provides faster and more effective intragastric acid control than pantoprazole 40 mg i.v.: results of a randomized study.
Wilder-Smith CH; Röhss K; Bondarov P; Hallerbäck B; Svedberg LE; Ahlbom H
Aliment Pharmacol Ther; 2004 Nov; 20(10):1099-104. PubMed ID: 15569112
[TBL] [Abstract][Full Text] [Related]
18. Effect of intravenous application of esomeprazole 40 mg versus pantoprazole 40 mg on 24-hour intragastric pH in healthy adults.
Hartmann D; Eickhoff A; Damian U; Riemann JF; Schilling D
Eur J Gastroenterol Hepatol; 2007 Feb; 19(2):133-7. PubMed ID: 17272998
[TBL] [Abstract][Full Text] [Related]
19. A single dose of intravenous esomeprazole decreases gastric secretion in healthy volunteers.
Nichita C; Abdou AE; Maerten P; Herranz M; Mouret N; Thalmann C; Michetti PF; Dorta G
Aliment Pharmacol Ther; 2009 Nov; 30(10):1022-9. PubMed ID: 19702644
[TBL] [Abstract][Full Text] [Related]
20. Current status of acid pump antagonists (reversible PPIs).
Wurst W; Hartmann M
Yale J Biol Med; 1996; 69(3):233-43. PubMed ID: 9165692
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
